Login to Your Account

Micurx kicks off U.S. MRX-1 phase II, looks to top Zyvox for drug-resistant bacteria infections

By Shannon Ellis
Staff Writer

Wednesday, March 4, 2015

A trans-Pacific biotech – with labs in Zhangjiang Hi-tech Park in Shanghai, and offices in Hayward, Calif. – Micurx Pharmaceuticals Inc., has commenced enrollment for its U.S. phase II trial for MRX-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription